NEW OPPORTUNITIES OF TREATMENT OF DIFFERENT TYPES OF JUVENILE ARTHRITIS WITH MONOCLONAL ANTIBODIES TO THE INTERLEUKIN 6 RECEPTOR

<p><em>The article observes the data on the role of interleukin (IL) 6 in pathogenesis of rheumatoid arthritis and treatment of rheumatoid arthritis and different types of juvenile arthritis with blocker IL 6 receptor (tocilizumab). The data on multicenter open-labeled and double-blinded...

Full description

Bibliographic Details
Main Authors: E.I. Alexeeva, R.V. Denisova, S.I. Valieva, T.M. Bzarova, A.O. Lisitsyn
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2010-01-01
Series:Voprosy Sovremennoj Pediatrii
Online Access:http://vsp.spr-journal.ru:80/jour/article/view/828
Description
Summary:<p><em>The article observes the data on the role of interleukin (IL) 6 in pathogenesis of rheumatoid arthritis and treatment of rheumatoid arthritis and different types of juvenile arthritis with blocker IL 6 receptor (tocilizumab). The data on multicenter open-labeled and double-blinded randomized studies on effectiveness and safety of tocilizumab are reviewed. The results of studies showed high effectiveness and safety of tocilizumab in treatment of rheumatoid arthritis and juvenile arthritis. </em><strong><em></em></strong></p><p><strong><em>Key words: children, rheumatoid arthritis, juvenile arthritis, interleukin 6, treatment, tocilizumab.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em><em>Voprosy sovremennoi pediatrii — </em></em></em>Current Pediatrics. 2010;9(1):52-61)</em></span></p>
ISSN:1682-5527
1682-5535